Charles Schwab’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Charles Schwab’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,969	Closed	-$16K	–	3211
2019 Q2	$16K	Sell	17,969 -30,497	-63%	-$47.7K	﹤0.01%	3208
2019 Q1	$113K	Buy	48,466 +17,969	+59%	+$48.7K	﹤0.01%	3084
2018 Q4	$71K	Sell	30,497 -5,000	-14%	-$44.1K	﹤0.01%	3113
2018 Q3	$527K	Buy	35,497 +8,597	+32%	+$137K	﹤0.01%	2816
2018 Q2	$409K	Hold	26,900	–	–	﹤0.01%	2862
2018 Q1	$506K	Buy	+26,900	New	+$470K	﹤0.01%	2728

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Charles Schwab's SNNA Position: Q3 2019 in Review

Charles Schwab sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 17,969 shares — an estimated $16K sold.

Charles Schwab first reported a position in SNNA in Q1 2018 and held it in 6 quarters. The position peaked at $527K in Q3 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Charles Schwab reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Charles Schwab sold 17,969 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $16K.
Charles Schwab first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 6 quarters.
Charles Schwab's Sienna Biopharmaceuticals, Inc. position peaked at $527K in Q3 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Charles Schwab's 13F filing for Q3 2019, filed 8 Nov 2019.